SCHEMBL2951228

SCHEMBL2951228

CC(C)C(CO)Nc1ccc2ncc(-c3cccc(OC(F)(F)F)c3)n2n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 8/20 0.69
PIM1 P11309 11/20 0.67
DYRK3 O43781 1/20 0.63
CCNT1 O60563 1/20 0.63
CCNA2 P20248 1/20 0.63
CDK2 P24941 1/20 0.63
CDK9 P50750 1/20 0.63
CDK5 Q00535 1/20 0.63
DYRK1A Q13627 1/20 0.63
CDK5R1 Q15078 1/20 0.63
DYRK2 Q92630 1/20 0.63
DYRK1B Q9Y463 1/20 0.63
GAK O14976 1/20 0.59
STK10 O94804 1/20 0.59
YES1 P07947 1/20 0.59
RET P07949 1/20 0.59
PDGFRB P09619 1/20 0.59
CSNK2A2 P19784 1/20 0.59
FLT3 P36888 1/20 0.59
ACVR1 Q04771 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951225 1.00 FYN (0.69) FYNPIM1DYRK3CCNT1CCNA2
SCHEMBL16331965 0.87 FYN (0.73) FYNDYRK3CCNT1CCNA2CDK2
SCHEMBL102764 0.87 FYN (0.79) FYNPIM1DYRK3CCNT1CCNA2
SCHEMBL102236 0.87 FYN (0.79) FYNPIM1DYRK3CCNT1CCNA2
SCHEMBL2950265 0.85 DYRK1A (0.75) FYNPIM1DYRK3CCNT1CCNA2
SCHEMBL2950267 0.85 DYRK1A (0.75) FYNPIM1DYRK3CCNT1CCNA2
SCHEMBL2946453 0.83 FYN (0.79) FYNDYRK3CCNT1CCNA2CDK2
SCHEMBL19987042 0.83 PIM1 (0.76) FYNPIM1DYRK1AGAKSTK10
SCHEMBL20485745 0.82 FYN (1.00) FYNDYRK3CCNT1CCNA2CDK2
SCHEMBL20485748 0.82 FYN (1.00) FYNDYRK3CCNT1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885PIM1 365/4885DYRK3 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.